Polycystic Kidney Disease Market

 Market Overview:

The 7 major polycystic kidney disease markets reached a value of US$ 358.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 622.1 Million by 2034, exhibiting a growth rate (CAGR) of 5.15% during 2024-2034.

The polycystic kidney disease market has been comprehensively analyzed in IMARC's new report titled "Polycystic Kidney Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Polycystic kidney disease (PKD) stands for a genetic disorder that is characterized by the growth of numerous cysts in the kidneys. These cysts are filled with fluid and can gradually enlarge, which can cause the kidneys to become larger and heavier over time. The most common symptom of the ailment is pain in the back or sides caused by the enlarged kidneys pressing against other organs. Additional indications can include headaches, high blood pressure, frequent urination, blood in the urine, kidney stones, etc. The diagnosis of the ailment typically involves a combination of physical examination, medical history, imaging tests, and genetic testing. The presence of multiple cysts in the kidneys is a hallmark of the disease, and imaging tests can help detect their size, number, and location. Blood and urine tests may also be conducted to assess kidney function and rule out other possible causes of cyst formation. In some cases, genetic testing may be used to confirm the prognosis and identify the specific genetic mutation responsible for the disease.

The increasing cases of gene mutations that lead to the development of cysts in the kidneys, which can grow and eventually damage the surrounding tissue, are primarily driving the polycystic kidney disease market. Moreover, the escalating utilization of antibiotics, such as nitrofurantoin, cephalexin, trimethoprim-sulfamethoxazole, etc., to prevent recurrent urinary tract infections in people with PKD who have a history of frequent infections is also augmenting the market growth. Besides this, the widespread adoption of cyst drainage for relieving pain and discomfort caused by large, symptomatic cysts that are not responsive to other treatments, including pain management and lifestyle modifications, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of peritoneal dialysis over hemodialysis on account of its several associated benefits, such as lower risk of infection, fewer dietary restrictions, convenience, etc., is also bolstering the market growth. Furthermore, the introduction of contrast-enhanced ultrasonography (CEUS), which uses a contrast agent to improve the visualization of blood vessels and cysts in the kidneys, thereby improving the accuracy and precision of PKD diagnosis and monitoring, is expected to drive the polycystic kidney disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the polycystic kidney disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for polycystic kidney disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the polycystic kidney disease market in any manner.

Recent Developments:

• In June 2024, Regulus Therapeutics reported favorable topline findings from the third cohort of patients in its Phase 1b MAD trial of RGLS8429 for the management of autosomal dominant polycystic kidney disease (ADPKD). The Phase 1b MAD study is a placebo-controlled, double-blind trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of RGLS8429 in adult patients with ADPKD.
• In May 2024, Rege Nephro CO., Ltd. stated that patient recruitment was initiated in April for the second stage of its Phase II clinical study of tamibarotene as a developing product for the treatment of ADPKD under the code RN-014. After assessing all available safety data from the first stage, which began in December of last year, it was decided to proceed to the second step.
• In January 2024, XORTX Therapeutics announced the filing of a new patent for the management of chronic kidney disease. This patent is intended to protect new discoveries and strategies for treating individuals with varying levels of kidney function in the context of CKD. Importantly, this patent titled "Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease" describes new formulations and methods for using xanthine oxidase inhibitors (XOI) in the setting of CKD, specifically autosomal dominant polycystic kidney disease.
• In September 2023, Boehringer Ingelheim and Eli Lilly and Company announced that the FDA had approved Jardiance (empagliflozin) 10 mg tablets to lower the risk of hospitalization, end-stage kidney disease, cardiovascular death, and sustained decline in estimated glomerular filtration rate (eGFR) in adults with chronic kidney disease at risk of progression.

Key Highlights:

• Approximately 500,000 people in the United States suffer from PKD.
• ADPKD accounts for approximately 90% of all PKD cases.
• There is a 1:1000 reported frequency of ADPKD, which affects all races.
• The condition is more prevalent in men than in women.
• PKD is responsible for almost 10% of all end-stage renal disease.

Drugs:

Jynarque is a selective vasopressin V2-receptor antagonist indicated to delay kidney function decline in persons at risk of fast advancing ADPKD. JYNARQUE's starting dosage is 60 mg orally per day, with 45 mg taken at awakening and 15 mg administered 8 hours later.

RGLS8429 is an innovative next-generation oligonucleotide for treating ADPKD that inhibits miR-17 and preferentially targets the kidney. Administration of RGLS8429 significantly improved kidney function, size, and other disease severity indicators in preclinical models. Regulus stated that the Phase 1 SAD research was concluded in September 2022. The Phase 1 SAD research showed that RGLS8429 had a positive safety and pharmacokinetic profile.

Bardoxolone methyl is a small molecular structure that activates the nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor involved in the body's stress response. This compound's anti-oxidant and anti-inflammatory properties may improve kidney function. In the phase 2 clinical study done in Japan (TSUBAKI), the administration of bardoxolone methyl resulted in a significant improvement in glomerular filtration rate (kidney function) as determined by the inulin clearance method.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the polycystic kidney disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the polycystic kidney disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current polycystic kidney disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the polycystic kidney disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the polycystic kidney disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the polycystic kidney disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of polycystic kidney disease across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of polycystic kidney disease by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of polycystic kidney disease by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of polycystic kidney disease by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with polycystic kidney disease across the seven major markets?
• What is the size of the polycystic kidney disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of polycystic kidney disease?
• What will be the growth rate of patients across the seven major markets?
   

Polycystic Kidney Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for polycystic kidney disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the polycystic kidney disease market?
• What are the key regulatory events related to the polycystic kidney disease market?
• What is the structure of clinical trial landscape by status related to the polycystic kidney disease market?
• What is the structure of clinical trial landscape by phase related to the polycystic kidney disease market?
• What is the structure of clinical trial landscape by route of administration related to the polycystic kidney disease market?